Evotec has achieved key milestones in its partnership with Bristol Myers Squibb in the field of targeted protein degradation with the first two targets transitioning into drug discovery after completing a comprehensive target validation process.   The companies entered a long-term strategic discovery and development partnership in 2018 with the goal to identify novel drug targets. The partnership leverages Evotec’s PanOmics platform, which combines enhanced throughput proteomics, high th...